Skip to menu Skip to content Skip to footer

2014

Conference Publication

The nano-bio interface

Wolfram, Joy (2014). The nano-bio interface. Mini-Workshop for Nanosystems and Health Science, Catanzaro, Italy, July 2014.

The nano-bio interface

2014

Conference Publication

Shrinkage of pegylated and non-pegylated liposomes in serum

Wolfram, Joy (2014). Shrinkage of pegylated and non-pegylated liposomes in serum. European Summit for Clinical Nanomedicine and Targeted Medicine, Basel, Switzerland , June 2014.

Shrinkage of pegylated and non-pegylated liposomes in serum

2014

Conference Publication

Shrinkage of pegylated and non-pegylated liposomes in serum

Wolfram, Joy, Yang, Yong, Celia, Christian, Shen, Haifa, Zhao, Yuliang and Ferrari, Mauro (2014). Shrinkage of pegylated and non-pegylated liposomes in serum. NanoBio-Europe: International Congress & Exhibition on Nanobiotechnology, Münster, Germany , June 2014.

Shrinkage of pegylated and non-pegylated liposomes in serum

2014

Conference Publication

Celastrol-loaded liposomes as nano-drugs for the potential treatment of prostate cancer

Wolfram, Joy, Celia, Christian, Borsoi, Carlotta, Moten, Asad, Paolino, Donatella, Fresta, Massimo, Shen, Haifa, Ferrari, Mauro, Di Marzio, Luisa and Carafa, M. (2014). Celastrol-loaded liposomes as nano-drugs for the potential treatment of prostate cancer. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lisbon, Portugal , April 2014.

Celastrol-loaded liposomes as nano-drugs for the potential treatment of prostate cancer

2014

Conference Publication

Bergamot essential oil (BEO)-loaded liposomes: nanoformulation for anticancer activity on neuroblastoma cells

Celia, Christian, Trapasso, E., Locatelli, M., Cosco, D., Ventura, C. A., Wolfram, Joy, Carafa, M., Di Marzio, Luisa and Paolino, Donatella (2014). Bergamot essential oil (BEO)-loaded liposomes: nanoformulation for anticancer activity on neuroblastoma cells. 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lisbon, Portugal , April 2014.

Bergamot essential oil (BEO)-loaded liposomes: nanoformulation for anticancer activity on neuroblastoma cells

2013

Conference Publication

Joint collaboration between the National Center for Nanoscience and Technology (NCNST) and the Houston Methodist Hospital

Wolfram, Joy, Ferrari, Mauro and Zhao, Yuliang (2013). Joint collaboration between the National Center for Nanoscience and Technology (NCNST) and the Houston Methodist Hospital. ChinaNano2013: International Conference on Nanoscience and Technology, Beijing, China , September 2013.

Joint collaboration between the National Center for Nanoscience and Technology (NCNST) and the Houston Methodist Hospital

2013

Conference Publication

Polyarginine induces an antitumor immune response through binding to toll-like receptor 4 (TLR4)

Yang, Yong, Wolfram, Joy, Shen, Haifa, Fang, X. and Ferrari, Mauro (2013). Polyarginine induces an antitumor immune response through binding to toll-like receptor 4 (TLR4). ChinaNano2013: International Conference on Nanoscience and Technology, Beijing, China, September 2013.

Polyarginine induces an antitumor immune response through binding to toll-like receptor 4 (TLR4)

2012

Conference Publication

Toward understanding and overcoming multiscale mass transport differentials in cancer

Koay, Eugene, Kirui, Dickson, Yang, Yubo, Wolfram, Joy, Shen, Haifa and Ferrari, Mauro (2012). Toward understanding and overcoming multiscale mass transport differentials in cancer. Third Annual Physical Sciences – Oncology Centers (PS-OCs) Investigators Meeting, Tampa, FL United States , April 2012.

Toward understanding and overcoming multiscale mass transport differentials in cancer

2009

Conference Publication

Angiomotin-like protein 2 (AmotL2), a potential target for cancer therapy

Wolfram, Joy, Mojallal, M., Zheng, Y. and Holmgren, L. (2009). Angiomotin-like protein 2 (AmotL2), a potential target for cancer therapy. Amgen Scholars Symposium, Cambridge, United Kingdom, September 2009.

Angiomotin-like protein 2 (AmotL2), a potential target for cancer therapy